{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T11:03:44Z","timestamp":1771585424354,"version":"3.50.1"},"posted":{"date-parts":[[2026,1,19]]},"group-title":"In Review","reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,10,3]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Background\n The use of immune checkpoint inhibitors (ICIs) has led to a paradigm change in cancer management. Many patients may have inherent primary resistance to ICIs or develop secondary resistance after initial response. The impact of using novel therapeutic combinations of checkpoint blockade (avelumab) with immune stimulating agonists such as anti- OX40 and\/or anti- 4-1BB on the tumor microenvironment and modulation of the immune response is an intriguing strategy to evaluate how these agents interact and whether the hypothetical rationale for combinations can be translated into augmentation of anti-tumor immunity in solid tumors.\nMethods\n We performed whole exome sequencing (WES), bulk RNAseq, multiplex immunofluorescence (mIF) and chromogenic immunohistochemistry (IHC) on tumor tissue and flow cytometry of the peripheral blood to study longitudinal changes following the combination of avelumab with utomilumab (a 4-1BB agonist) (arm A), PF-04518600 (an OX40 agonist) (arm B), utomilumab and PF-04518600 (arm C) and utomilumab and radiotherapy (arm D) in phase I\/II study (NCT03217747).\nResults\n We observed low tumor mutation burden (TMB\u2009&lt;\u20096) (median: 1.88), alteration of RTK-RAS, TP53, PI3K and WNT pathways across the cohorts. Mutations in\n                  <italic>TP53<\/italic>\n                  ,\n                  <italic>TTN<\/italic>\n                  and\n                  <italic>KRAS<\/italic>\n                  (mostly p.G12C, p.G12D) genes and copy number variations (CNV) were found in\n                  <italic>PIK3CA<\/italic>\n                  ,\n                  <italic>CCNE1<\/italic>\n                  and\n                  <italic>KRAS<\/italic>\n                  . Interferon gamma signaling pathway was enriched early on-treatment in tumors from patients with colorectal and pancreatic cancers in arm C. Patients deriving clinical benefit (CR\/PR\/SD\u2009\u2265\u20094 months) displayed higher T-cell frequencies at baseline (p\u2009=\u20090.0157), C1D15 (p\u2009=\u20090.0086), and C3D15 (p\u2009=\u20090.0070) than patients without clinical benefit.\nConclusions\n Our findings, though limited, highlight genomic differences between histologic subsets and outcome as well as the need for combination strategies that drive the recruitment and\/or priming of anti-tumor T cells and address low immune permissive tumor states in patients with advanced solid tumors.\nClinical trial registration:\n This clinical trial was registered on clinicaltrials.gov NCT03217747.\n                <\/p>","DOI":"10.21203\/rs.3.rs-7775526\/v1","type":"posted-content","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:05:52Z","timestamp":1768813552000},"source":"Crossref","is-referenced-by-count":0,"title":["Tumor microenvironment changes after treatment with avelumab and immune- stimulating agent combinations in patients with advanced solid tumors"],"prefix":"10.21203","author":[{"given":"Nejla Ozirmak","family":"Lermi","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A","family":"Gouda","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jibran","family":"Ahmed","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianli","family":"Jiang","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Younghee","family":"Lee","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vakul","family":"Mohanty","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Derbala","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettzy","family":"Stephen","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuja","family":"Jhingran","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Moustafa","family":"Mohammad","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghyun","family":"Joo","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Francisco-Cruz","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honglei","family":"Chen","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Acosta","family":"Calderon","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caddie","family":"Laberiano","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Arrechedera","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renganayaki","family":"Pandurengan","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serdar","family":"Gurses","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yali","family":"Yang","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa M. Solis","family":"Soto","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi Rodon","family":"Ahnert","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Chen","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene Jon","family":"Koay","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milind","family":"Javle","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara","family":"Haymaker","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins RW","year":"2018","unstructured":"Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118(1):9\u201316.","journal-title":"Br J Cancer"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield LH","year":"2024","unstructured":"Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024;24(6):399\u2013416.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000573","article-title":"New pathways in immune stimulation: targeting OX40","volume":"5","author":"Alves Costa Silva C","year":"2020","unstructured":"Alves Costa Silva C, Facchinetti F, Routy B, Derosa L. New pathways in immune stimulation: targeting OX40. ESMO Open. 2020;5(1).","journal-title":"ESMO Open"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s12276-023-01136-4","article-title":"4-1BB immunotherapy: advances and hurdles","volume":"56","author":"Singh R","year":"2024","unstructured":"Singh R, Kim YH, Lee SJ, Eom HS, Choi BK. 4-1BB immunotherapy: advances and hurdles. Exp Mol Med. 2024;56(1):32\u20139.","journal-title":"Exp Mol Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.2147\/OTT.S214211","article-title":"OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer","volume":"12","author":"Deng J","year":"2019","unstructured":"Deng J, Zhao S, Zhang X, Jia K, Wang H, Zhou C, He Y. OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer. Oncotargets Ther. 2019;12:7347\u201353.","journal-title":"Oncotargets Ther"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5483\/BMBRep.2014.47.3.283","article-title":"4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy","volume":"47","author":"Vinay DS","year":"2014","unstructured":"Vinay DS, Kwon BS. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep. 2014;47(3):122\u20139.","journal-title":"BMB Rep"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1158\/2326-6066.CIR-14-0118","article-title":"Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector\/memory CD8 T cells in a poorly immunogenic tumor model","volume":"3","author":"Chen S","year":"2015","unstructured":"Chen S, Lee LF, Fisher TS, Jessen B, Elliott M, Evering W, et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector\/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol Res. 2015;3(2):149\u201360.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf032","article-title":"A phase I\/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies","volume":"30","author":"Ahmed J","year":"2025","unstructured":"Ahmed J, Knisely A, Torrado C, Stephen B, Yang Y, Song J, et al. A phase I\/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies. Oncologist. 2025;30(3).","journal-title":"Oncologist"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/cncr.35063","article-title":"Phase 1\/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies","volume":"130","author":"Knisely A","year":"2024","unstructured":"Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, et al. Phase 1\/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer. 2024;130(3):400\u20139.","journal-title":"Cancer"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00262-012-1237-1","article-title":"Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity","volume":"61","author":"Fisher TS","year":"2012","unstructured":"Fisher TS, Kamperschroer C, Oliphant T, Love VA, Lira PD, Doyonnas R, et al. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother. 2012;61(10):1721\u201333.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/1078-0432.CCR-21-0845","article-title":"A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers","volume":"28","author":"Diab A","year":"2022","unstructured":"Diab A, Hamid O, Thompson JA, Ros W, Eskens F, Doi T, et al. A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. Clin Cancer Res. 2022;28(1):71\u201383.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005471","article-title":"First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors","volume":"10","author":"Hamid O","year":"2022","unstructured":"Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens F, et al. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. J Immunother Cancer. 2022;10(10).","journal-title":"J Immunother Cancer"},{"issue":"14","key":"ref13","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows\u2013Wheeler transform","volume":"25","author":"Li H","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics. 2009;25(14):1754\u201360.","journal-title":"Bioinformatics"},{"key":"ref14","unstructured":"Picard Toolkit Broad Institute, GitHub repository: Broad Institute; 2019 [Available from: https:\/\/broadinstitute.github.io\/picard\/."},{"key":"ref15","first-page":"1367","article-title":"Bias from removing read duplication in ultra-deep sequencing experiments","author":"Zhou W","unstructured":"Zhou W, Chen T, Zhao H, Eterovic AK, Meric-Bernstam F, Mills GB, Chen K. Bias from removing read duplication in ultra-deep sequencing experiments. (1367\u20134811 (Electronic))."},{"key":"ref16","author":"Lonigro RJ","unstructured":"Lonigro RJ, Grasso Cs Fau - Robinson DR, Robinson Dr Fau - Jing X, Jing X Fau - Wu Y-M, Wu Ym Fau - Cao X, Cao X Fau - Quist MJ, et al. Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. (1476\u20135586 (Electronic))."},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic Signaling Pathways in The Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega F","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018;173(2):321\u2009\u2013\u200937.e10.","journal-title":"Cell"},{"key":"ref18","author":"Team R","year":"2020","unstructured":"Team R. RStudio: Integrated Development for R: RStudio, PBC, Boston, MA; 2020 [Available from: http:\/\/www.rstudio.com\/."},{"key":"ref19","first-page":"1549","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","author":"Mayakonda AA-OX","unstructured":"Mayakonda AA-OX, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. (1549\u20135469 (Electronic))."},{"key":"ref20","author":"Zhang J","unstructured":"Zhang J. CNTools: Convert segment data into a region by sample matrix to allow for other high level computational analyses 2024 [Available from: https:\/\/bioconductor.org\/packages\/devel\/bioc\/html\/CNTools.html."},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham H","year":"2016","unstructured":"Wickham H. ggplot2: Elegant Graphics for Data Analysis: Springer-Verlag New York; 2016."},{"key":"ref22","first-page":"1367","article-title":"STAR: ultrafast universal RNA-seq aligner","author":"Dobin A","unstructured":"Dobin A, Davis Ca Fau - Schlesinger F, Schlesinger F Fau - Drenkow J, Drenkow J Fau - Zaleski C, Zaleski C Fau - Jha S, Jha S Fau - Batut P, et al. STAR: ultrafast universal RNA-seq aligner. (1367\u20134811 (Electronic))."},{"key":"ref23","first-page":"1367","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","author":"Liao Y","unstructured":"Liao Y, Smyth Gk Fau - Shi W, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. (1367\u20134811 (Electronic))."},{"key":"ref24","author":"Andrews S","unstructured":"Andrews S. FastQC A Quality Control tool for High Throughput Sequencing Data 2010 [Available from: https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/."},{"key":"ref25","author":"Okonechnikov K","unstructured":"Okonechnikov K, Conesa A, Garc\u00eda-Alcalde F. Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data. (1367\u20134811 (Electronic))."},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love MI","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology. 2014;15(12):550.","journal-title":"Genome Biology"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini Y","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological). 1995;57(1):289\u2013300.","journal-title":"Journal of the Royal Statistical Society Series B (Methodological)"},{"issue":"7","key":"ref28","doi-asserted-by":"crossref","first-page":"e47-e","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie ME","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research. 2015;43(7):e47-e.","journal-title":"Nucleic Acids Research"},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman AM","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nature Biotechnology. 2019;37(7):773\u201382.","journal-title":"Nature Biotechnology"},{"key":"ref30","author":"Subramanian A","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences. 2005;102(43):15545-50."},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha VK","year":"2003","unstructured":"Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genetics. 2003;34(3):267\u201373.","journal-title":"Nature Genetics"},{"key":"ref32","author":"Blighe K","unstructured":"Blighe K, S Rana, and M Lewis. EnhancedVolcano: Publication-ready volcano plots with enhanced colouring and labeling 2018 [Available from: https:\/\/github.com\/kevinblighe\/EnhancedVolcano."},{"issue":"18","key":"ref33","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu Z","year":"2016","unstructured":"Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32(18):2847\u20139.","journal-title":"Bioinformatics"},{"issue":"24","key":"ref34","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.1158\/1078-0432.CCR-15-2443","article-title":"Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients","volume":"22","author":"Parra ER","year":"2016","unstructured":"Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, et al. Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. Clin Cancer Res. 2016;22(24):6278\u201389.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/PAI.0000000000000531","article-title":"Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma","volume":"26","author":"Parra ER","year":"2018","unstructured":"Parra ER, Villalobos P, Mino B, Rodriguez-Canales J. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol. 2018;26(2):83\u201393.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"2388304","DOI":"10.1080\/2162402X.2024.2388304","article-title":"Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma","volume":"13","author":"Sol\u00f3rzano JL","year":"2024","unstructured":"Sol\u00f3rzano JL, Men\u00e9ndez V, Parra E, Solis L, Salazar R, Garc\u00eda-Cos\u00edo M, et al. Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma. Oncoimmunology. 2024;13(1):2388304.","journal-title":"Oncoimmunology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"100074","DOI":"10.1016\/j.adcanc.2022.100074","article-title":"Insights into therapy resistance in cervical cancer","volume":"6","author":"George IA","year":"2022","unstructured":"George IA, Chauhan R, Dhawale RE, Iyer R, Limaye S, Sankaranarayanan R, et al. Insights into therapy resistance in cervical cancer. Advances in Cancer Biology - Metastasis. 2022;6:100074.","journal-title":"Advances in Cancer Biology - Metastasis"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1186357","DOI":"10.3389\/fimmu.2023.1186357","article-title":"Unveiling the interplay between mutational signatures and tumor microenvironment: a pan-cancer analysis","volume":"14","author":"Luo LZ","year":"2023","unstructured":"Luo LZ, Li S, Wei C, Ma J, Qian LM, Chen YX, et al. Unveiling the interplay between mutational signatures and tumor microenvironment: a pan-cancer analysis. Front Immunol. 2023;14:1186357.","journal-title":"Front Immunol"},{"issue":"3","key":"ref39","first-page":"48","article-title":"APOBEC3B expression has prognostic significance in cervical cancer","volume":"16","author":"Zhang SQ","year":"2023","unstructured":"Zhang SQ, Zhang J, Yu Y, Yu MM, Wei J, Tang YH. APOBEC3B expression has prognostic significance in cervical cancer. Int J Clin Exp Pathol. 2023;16(3):48\u201356.","journal-title":"Int J Clin Exp Pathol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7775526\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7775526\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T10:09:49Z","timestamp":1771582189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7775526\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":39,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-7775526\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,1,19]]},"subtype":"preprint"}}